Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
PTLA closed up 46.56 percent on Friday, June 23, 2017, on 10.63 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Trend Table & Recent Alerts
|Weak or Absent||Up||Up||Up|
|See historical PTLA trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 23||Crossed Above 50 DMA||Bullish||0.00%|
|Jun 23||New 52 Week High||Bullish||0.00%|
|Jun 23||Volume Surge||Other||0.00%|
|Jun 23||Wide Range Bar||Range Expansion||0.00%|
|Jun 23||Reversal New Highs Setup||Bullish Swing Setup||0.00%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more PTLA news...
|52 Week High||57.9|
|52 Week Low||15.68|
|200-Day Moving Average||29.1908|
|50-Day Moving Average||38.8958|
|20-Day Moving Average||38.1085|
|10-Day Moving Average||39.098|
|Average True Range||3.2002|
|Chandelier Exit (Long, 3 ATRs)||48.2994|
|Chandelier Exit (Short, 3 ATRs)||42.1706|
|Upper Bollinger Band||46.5964|
|Lower Bollinger Band||29.6206|
|Percent B (%b)||1.56|
|MACD Signal Line||-0.0853|